AllTranz
Lexington
About AllTranz
AllTranz is a specialty pharmaceutical company developing a unique set of dermal delivery products utilizing two proprietary technology platforms consisting of prodrug development and microneedle formulations. AllTranz will be a leader in the development of innovative drug design strategies delivered via unique dermal product solutions to treat neurological and a variety of other disorders. The broad range of offerings includes solutions for pain modulation, appetite stimulation, smoking cessation, substitution treatment for opiate addiction, as well as alcohol abuse, and abuse deterrent formulations for opiates. AllTranz will utilize its unique dermal drug delivery technology to develop its own products for broad market appeal, as well as partner with pharmaceutical companies seeking to leverage the AllTranz technology platform to improve delivery of existing drugs to form new chemical entities thereby extending patent franchises.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $860.0K
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2007)
- Website: alltranz.com
- Phone: 4107060886
Industries & Categories
Addiction Treatment, Health Care, Medical, Neuroscience, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/alltranz-2733061 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.